Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.

Introducción: el dolor neuropático es una patología de considerable prevalencia e impacto socio-económico en la población latinoamericana, la evidencia clínica sugiere que los ligandos de canales de calcio y el parche de Lidocaína pueden tratar exitosamente el dolor neuropático periférico y localiza...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2013
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
spa
OAI Identifier:
oai:repository.urosario.edu.co:10336/4440
Acceso en línea:
https://doi.org/10.48713/10336_4440
http://repository.urosario.edu.co/handle/10336/4440
Palabra clave:
Gabapentina
Pregabalina
Lidocaina
Costo-efectividad
dolor
Gabapentin
Pregabalin
Lidocaine
Cost-effectiveness
pain
Atención médica::Aspectos Económicos
Enfermedades del sistema nervioso::Tratamiento
Gabapentina::Utilización
Lidocaína::Utilización
Pregabalina::Utilización
Rights
License
Abierto (Texto completo)
id EDOCUR2_ee9e3629321e00c52e61631d32a3648b
oai_identifier_str oai:repository.urosario.edu.co:10336/4440
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.spa.fl_str_mv Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
title Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
spellingShingle Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
Gabapentina
Pregabalina
Lidocaina
Costo-efectividad
dolor
Gabapentin
Pregabalin
Lidocaine
Cost-effectiveness
pain
Atención médica::Aspectos Económicos
Enfermedades del sistema nervioso::Tratamiento
Gabapentina::Utilización
Lidocaína::Utilización
Pregabalina::Utilización
title_short Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
title_full Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
title_fullStr Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
title_full_unstemmed Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
title_sort Estudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.
dc.contributor.advisor.none.fl_str_mv Trillos Peña, Carlos Enrique
dc.subject.spa.fl_str_mv Gabapentina
Pregabalina
Lidocaina
Costo-efectividad
dolor
topic Gabapentina
Pregabalina
Lidocaina
Costo-efectividad
dolor
Gabapentin
Pregabalin
Lidocaine
Cost-effectiveness
pain
Atención médica::Aspectos Económicos
Enfermedades del sistema nervioso::Tratamiento
Gabapentina::Utilización
Lidocaína::Utilización
Pregabalina::Utilización
dc.subject.keyword.eng.fl_str_mv Gabapentin
Pregabalin
Lidocaine
Cost-effectiveness
pain
dc.subject.lemb.spa.fl_str_mv Atención médica::Aspectos Económicos
Enfermedades del sistema nervioso::Tratamiento
Gabapentina::Utilización
Lidocaína::Utilización
Pregabalina::Utilización
description Introducción: el dolor neuropático es una patología de considerable prevalencia e impacto socio-económico en la población latinoamericana, la evidencia clínica sugiere que los ligandos de canales de calcio y el parche de Lidocaína pueden tratar exitosamente el dolor neuropático periférico y localizado. Metodología: se realizo una evaluación económica tipo costo-efectividad, observacional y retrospectiva con datos extraídos de las historias clínicas de pacientes atendidos en la clínica de dolor de la IPS. La variable primaria de efectividad fue la mejoría del dolor medida mediante escala visual análoga. Resultados: se estudiaron 94 pacientes tratados con: Gabapentina (G) 21, Pregabalina (P) 24, Gabapentina+ lidocaína (G/P) 24, Pregabalina + Lidocaína (P/L) 25, los costos asociados al tratamiento son los siguientes COP$114.070.835, COP$105.855.920, COP$88.717.481 COP$89.854.712 respectivamente, el número de pacientes con mejoría significativa de dolor fue: 8,10,9 y 21 pacientes respectivamente. El ICER de G/L con respecto a G fue: COP$ -25.353.354. El ICER de P/L con respecto a P fue: COP$ -1.454.655. Conclusiones: la adición del parche de lidocaína a la terapia regular con P/L represento una disminución de consumo de recursos en salud como uso de medicamentos co-analgésicos, analgésicos de rescate y fármacos para controlar reacciones adversas, de la misma forma que consultas a profesionales de la salud. Cada paciente manejado con P/L representa un ahorro de COP $1.454.655 al contrario si se manejase con el anticonvulsivante de manera exclusiva, en el caso de G/L este ahorro es de COP $ 25.353.354 frente a G sola.
publishDate 2013
dc.date.accessioned.none.fl_str_mv 2013-06-12T20:45:37Z
dc.date.available.none.fl_str_mv 2013-06-12T20:45:37Z
dc.date.created.none.fl_str_mv 2013-05-14
dc.date.issued.none.fl_str_mv 2013
dc.type.eng.fl_str_mv bachelorThesis
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.spa.spa.fl_str_mv Trabajo de grado
dc.identifier.doi.none.fl_str_mv https://doi.org/10.48713/10336_4440
dc.identifier.uri.none.fl_str_mv http://repository.urosario.edu.co/handle/10336/4440
url https://doi.org/10.48713/10336_4440
http://repository.urosario.edu.co/handle/10336/4440
dc.language.iso.none.fl_str_mv spa
language spa
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto completo)
dc.rights.cc.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
rights_invalid_str_mv Abierto (Texto completo)
Atribución-NoComercial-SinDerivadas 2.5 Colombia
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.format.tipo.spa.fl_str_mv Documento
dc.publisher.spa.fl_str_mv Universidad del Rosario
dc.publisher.department.spa.fl_str_mv Facultad de medicina
institution Universidad del Rosario
dc.source.bibliographicCitation.none.fl_str_mv 1. Acevedo J, Amaya A, De León Casasola O, Chinchilla N, De Giorgis M, Flórez S, et al. Guidelines for the Diagnosis and Management of Neuropathic Pain: Consensus of a Group of Latin American Experts. Journal of Pain & Palliative Care Pharmacotherapy.2009;23(3):261-281.
2. Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain.British Medical Journal.2009; 339: 391-395.
3. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology. 2006; 13:1153–1169.
4. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain:Evidence-based recommendations. Pain. 2007; 132: 237–251.
5. Finnerup NB, Otto M, MC Quay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005; 118: 289–305.
6. O’Connor AB, Dworkin RH. Treatment of Neuropathic Pain: An Overview of Recent Guidelines. The American Journal of Medicine. 2009; 122 (10A): S22-S32.
7. Sexto Estudio Nacional de Dolor. Disponible en: http://www.dolor.org.co/index.php?option=com_content&view=article&id=258&Itemid=87. Accesado: 10-Abril-2012.
8. Vorobeychik Y, Gordin V, Mao J, Chen L. Combination Therapy for Neuropathic Pain A Review of Current Evidence. CNS Drugs. 2011; 25 (12): 1023-1034.
9. Taylor RS. Epidemiology of refractory neuropathic pain. Pain Practice.2006; 6(1): 22-26.
10. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain.2006; 7(4):281-289.
11.Gilron I, Watson CPN, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. Canadian Medical Association Journal. 2006; 175(3):265-275.
12. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics.2009; 27(2): 95-112.
13. Pan American Health Organization. Country Health Profile for Colombia. 2001 Disponible en: http://www.paho.org/spanish/sha/prflcol.htm.Accesado: Marzo 5 de 2012.
14. Ritchie M, Liedgens H, Nuijten M. Cost Effectiveness of a Lidocaine 5% Medicated Plaster Compared with Pregabalin for the Treatment of Postherpetic Neuralgia in the UK, A Markov Model Analysis. Clinical Drug Investigation. 2010; 30 (2): 71-87.
15. Dakin H, Nuijten M, Liedgens H, Nautrup BP. Cost Effectiveness of a Lidocaine 5% Medicated Plaster Relative to Gabapentin for Postherpetic Neuralgia in the United Kingdom. Clinical Therapeutics. 2007;29 (7): 1-17.
16. Dray A. Neuropathic pain: emerging treatments. British Journal of Anaesthesia.2008;101 (1): 48–58.
17. Rabow MW, Pantilat SZ. Palliative Care & Pain Management. En: McPhee SJ, Papadakis MA eds. Current Medical diagnosis and Treatment.49th Ed. New York: Mc Graw Hill; 2010. P76-93.
18. Chrischilles EA. Cost-Effectiveness Analysis. En: Bootman JL, Townsend RJ, McGhan WE. Principles of Pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney; 1996. P77-101.
19. Rascati KL. Cost-Effectiveness Analysis. En: Rascati KL. Essentials of Pharmacoeconomics. Philadelphia: Lippincott Williams& Wilkins; 2009. P47-66.
20. Nayak S.Lidocaine 5% patch for localized chronic neuropathic pain in adolescents. Pediatric Anesthesia.2008;18(6):554-558.
21. Laird MA, Gidal BE. Use of gabapentin in the treatment of neuropathic pain. The Annals of Pharmacotherapy.2000;34(6): 802-807.
22. Hardman JG, Limbird LE, Goodman A eds.The Pharmacological Basis of Therapeutics. 10th ed. New York:McGraw-Hill;2001.
23. Durmus M, Kadir but A, Saricicek V, Ilksen Toprak H, Ozcan Ersoy M. The post-operative analgesic effects of a combination of gabapentin and paracetamol in patients undergoing abdominal hysterectomy: a randomized clinical trial. Acta Anaesthesiologica Scandinavica. 2007; 51: 299–304.
24. Gómez-Pérez FJ, Pérez-Monteverde A, Nascimento O, Aschner P, Tagle M, Fichtner K, etal. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. The British Journal of Diabetes & Vascular Disease. 2004; 4(3): 173 - 178.
25. Inserto aprobado por INVIMA Colombia Gabapentin 2012.
26. Blommel ML, Blommel AL. Pregabalin: An antiepileptic agent useful for neuropathic pain. American Journal of Health-System Pharmacy.2007; 64(14): 1475-1482.
27. Inserto aprobado por INVIMA Colombia Pregabalin 2012.
28. Comer AM, Lamb HM. Lidocaine Patch 5%.Drugs.2000; 59(2):245-249.
29. Davies PS, Galer BS. Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia. Drugs. 2004; 64 (9): 937-947.
30. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, Tolerability, and Impact on Quality of Life of the 5% Lidocaine Patch in Diabetic Polyneuropathy. Archives of Neurology. 2004;61:914-918.
31. Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5% for carpal tunnel syndrome: How it compares with injections: A pilot study. The Journal of Family Practice.2006; 55(3):209-214.
32. Habib AS, Polascik TJ, Weizer AZ, White WD, Moul JW, ElGasim MA, etal. Lidocaine Patch for Postoperative Analgesia After Radical Retropubic Prostatectomy. Anesthesia & Analgesia. 2009;108(6):1950 –1953.
33. Correa-Illanes G, Calderon W, Roa R, Piñeros JL, Dote J, Medina D. Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster. Local and Regional Anesthesia. 2010;3: 77–83.
34. Annemans L, Caekelbergh K, Morlion B, Hans G,De Cock P, Marbaix S. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clinica Belgica. 2008; 63(3): 170-178.
35. Doth AH, Hansson PT, Jensen MP, Taylor RS.The burden of neuropathic pain: A systematic review and meta-analysis of health utilities.Pain.2010;149:338–344.
36. Cepeda MS, Farrar JT. Economic Evaluation of Oral Treatments for Neuropathic Pain. The Journal of Pain.2006; 7(2):119-128.
37. Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, etal. Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. Journal of Medical Economics.2010; 13(3):472–481.
38. Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, etal. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or Pregabalin. Journal of Medical Economics. 2010; 13(3):482–491.
39. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clinical Therapeutics. 2006;28(11):1922-1934.
40. Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, etal. Cost-Effectiveness Analysis of a Lidocaine 5% Medicated Plaster Compared with Gabapentin and Pregabalin for Treating Postherpetic Neuralgia. Clinical Drug Investigation. 2008; 28 (9): 583-601.
41. Pérez C, Navarro A, Saldaña MT, Masramón X, Rejas J. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study. Clinical Therapeutics. 2010; 32(7):1357-70.
42. Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Current Medical Research and Opinion. 2007;23(10):2585-2596.
43. O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. Journal of the American Geriatrics Society. 2007; 55(8):1176-1184.
44. Sicras-Mainar A, Rejas-Gutierrez J, Navarro-Artieda R, Planas-Comes A. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain. Journal of Evaluation in Clinical Practice.2011. doi: 10.1111/j.1365-2753.2011.01752.x
45. Pérez C, Saldaña MT, Navarro A, Martínez S, Rejas J. Trigeminal Neuralgia Treated With Pregabalin in Family Medicine Settings: Its Effect on Pain Alleviation and Cost Reduction. Journal of Clinical Pharmacology. 2009; 49:582- 590.
46. Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.BMC Neurology.2011; 11(7): 1-11.
47. Saldaña MT, Navarro A, Pérez C, Masramón X, Rejas J. A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings. Pain Practice. 2010; 10(1): 31-41.
48. O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26(12):1045-1064.
49. Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Current Medical Research & Opinion. 2011;27(5):939-950.
50. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs. The Journal of Pain. 2010; 11(4):360-368.
51.Bouhassira D, LanteÅLri-Minet M, Attal N etal. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain.2008;136:380–387.
52.Smith A, Stijacic Cenzer I, Knight SJ etal. The Epidemiology of Pain During the Last 2 Years of Life. Ann Intern Med. 2010;153:563-569
53. Hernández N., Hernández J., Moreno C. Uso de los parches de lidocaína en el alivio del dolor neuropático localizado. Rev. Iberoamericana del Dolor N° 1, Vol 4, 2009
54. Smith KJ, Roberts MS. Secuencial medication strategies for postherpetic neuralgia: a cost effective analysis. J Pain 2007, 8 (5): 396-404.
55. Baron R, Mayoral V et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Current Medical Research and Opinion. July 2009 (25) 7: 1677-1687
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv https://repository.urosario.edu.co/bitstreams/3fd294a7-5aab-433a-9396-a8d07e4c5b81/download
https://repository.urosario.edu.co/bitstreams/79ae3bce-0a0b-44fc-b5b9-c4c808a2f5a5/download
https://repository.urosario.edu.co/bitstreams/300be21c-83df-4ff5-8466-abac692f436a/download
https://repository.urosario.edu.co/bitstreams/27ef5eb4-04f5-4fe8-8cde-587b72906b0d/download
https://repository.urosario.edu.co/bitstreams/f46bc37c-b06e-44c7-aa5f-0a528b6a2376/download
https://repository.urosario.edu.co/bitstreams/6528b5e7-d1e2-46f9-9ee6-daf0ee24aac0/download
https://repository.urosario.edu.co/bitstreams/527c7aec-22f9-4d1b-98cd-4664bfda2de7/download
https://repository.urosario.edu.co/bitstreams/6886d2d8-baaf-4c45-a834-ab85d0e9a34b/download
https://repository.urosario.edu.co/bitstreams/e71a6406-364e-481f-9742-353546904ded/download
https://repository.urosario.edu.co/bitstreams/e2066c7c-5680-43fd-ad82-f78c6461e539/download
bitstream.checksum.fl_str_mv 9f04b5a0b41c39c28cf5bd77d4af891c
4a1b9425ec860bc252becc65b1e76949
501eaa40a78b60e46098e6f8aa2bb95b
51e1d201d51cb527a2cdf276cec345f7
4b541ee1308bed0a9219513c5afdc9b6
bea4d6b2af765285c72632958378a5e6
d0ed4548228c2a99deb7c94749c7d107
f2afda8d294778aca31cf4c61c1f5516
5316d6a43dbf4d1fb49bb15b161d248e
93919197fc06e0461440c0e2e7f056d7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167549120610304
spelling Trillos Peña, Carlos Enrique79297795600Cifuentes, PaulHinestrosa, FranciscoEspecialista en Epidemiología (en Convenio con el CES)aba9e002-a0f9-420d-9d82-d3920488262b-109f20fb0-41e2-43bb-9a4d-1bb06d898145-12013-06-12T20:45:37Z2013-06-12T20:45:37Z2013-05-142013Introducción: el dolor neuropático es una patología de considerable prevalencia e impacto socio-económico en la población latinoamericana, la evidencia clínica sugiere que los ligandos de canales de calcio y el parche de Lidocaína pueden tratar exitosamente el dolor neuropático periférico y localizado. Metodología: se realizo una evaluación económica tipo costo-efectividad, observacional y retrospectiva con datos extraídos de las historias clínicas de pacientes atendidos en la clínica de dolor de la IPS. La variable primaria de efectividad fue la mejoría del dolor medida mediante escala visual análoga. Resultados: se estudiaron 94 pacientes tratados con: Gabapentina (G) 21, Pregabalina (P) 24, Gabapentina+ lidocaína (G/P) 24, Pregabalina + Lidocaína (P/L) 25, los costos asociados al tratamiento son los siguientes COP$114.070.835, COP$105.855.920, COP$88.717.481 COP$89.854.712 respectivamente, el número de pacientes con mejoría significativa de dolor fue: 8,10,9 y 21 pacientes respectivamente. El ICER de G/L con respecto a G fue: COP$ -25.353.354. El ICER de P/L con respecto a P fue: COP$ -1.454.655. Conclusiones: la adición del parche de lidocaína a la terapia regular con P/L represento una disminución de consumo de recursos en salud como uso de medicamentos co-analgésicos, analgésicos de rescate y fármacos para controlar reacciones adversas, de la misma forma que consultas a profesionales de la salud. Cada paciente manejado con P/L representa un ahorro de COP $1.454.655 al contrario si se manejase con el anticonvulsivante de manera exclusiva, en el caso de G/L este ahorro es de COP $ 25.353.354 frente a G sola.Abstract: Introduction: Neuropathic pain represents a considerable socio-economic burden with increasing prevalence among the Latin American population; the evidence suggests that calcium channel ligands (Pregabalin, Gabapentin) and the lidocain patch can successfully treat localized neuropathic pain. Methods: We performed an observational, retrospective cost effectiveness economic evaluation with data taken from the clinical records of patients consulting to the pain clinic of the insurer’s institution. The primary effectiveness variable was the Visual Analog Scale (VAS) improvement. Results. We had 94 patients fulfilling our inclusion criteria and were treated with either: Gabapentin (G) 21, Pregabaline (P) 24, Gabapentin + patch (G/L) 24, Pregabaline + patch (P/L) 25, the related costs are as follows respectively: COP$114.070.835, COP$105.855.920, COP$88.717.481 COP$89.854.712. The number of patients with a meaningful improvement in the pain scale (VAS) was: 8,10,9, and 21 respectively. The ICER for G/L compared to G was: COP$-25.353.354. The ICER for P/L compared to P was COP$-1.454.655. Conclusions. The addition of the lidocaine patch to standard therapy with either pregabaline or gabapentin decreased health resources consumption such as drugs used as co-analgesics, rescue analgesics and adverse event treatments, also it decreased the number of physician visits. We can conclude that for every patient treated with G/L the institution can save up to COP$25.353.354 instead of treatment with G alone. Equally patients treated with P/L represented a reduction in the institution’s budget consumption of COP$1.454.655 as compared to P alone.Grunenthalapplication/pdfDocumentohttps://doi.org/10.48713/10336_4440 http://repository.urosario.edu.co/handle/10336/4440spaUniversidad del RosarioFacultad de medicinaAbierto (Texto completo)Atribución-NoComercial-SinDerivadas 2.5 ColombiaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARÁGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización.http://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf21. Acevedo J, Amaya A, De León Casasola O, Chinchilla N, De Giorgis M, Flórez S, et al. Guidelines for the Diagnosis and Management of Neuropathic Pain: Consensus of a Group of Latin American Experts. Journal of Pain & Palliative Care Pharmacotherapy.2009;23(3):261-281.2. Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain.British Medical Journal.2009; 339: 391-395.3. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology. 2006; 13:1153–1169.4. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain:Evidence-based recommendations. Pain. 2007; 132: 237–251.5. Finnerup NB, Otto M, MC Quay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005; 118: 289–305.6. O’Connor AB, Dworkin RH. Treatment of Neuropathic Pain: An Overview of Recent Guidelines. The American Journal of Medicine. 2009; 122 (10A): S22-S32.7. Sexto Estudio Nacional de Dolor. Disponible en: http://www.dolor.org.co/index.php?option=com_content&view=article&id=258&Itemid=87. Accesado: 10-Abril-2012.8. Vorobeychik Y, Gordin V, Mao J, Chen L. Combination Therapy for Neuropathic Pain A Review of Current Evidence. CNS Drugs. 2011; 25 (12): 1023-1034.9. Taylor RS. Epidemiology of refractory neuropathic pain. Pain Practice.2006; 6(1): 22-26.10. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain.2006; 7(4):281-289.11.Gilron I, Watson CPN, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. Canadian Medical Association Journal. 2006; 175(3):265-275.12. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics.2009; 27(2): 95-112.13. Pan American Health Organization. Country Health Profile for Colombia. 2001 Disponible en: http://www.paho.org/spanish/sha/prflcol.htm.Accesado: Marzo 5 de 2012.14. Ritchie M, Liedgens H, Nuijten M. Cost Effectiveness of a Lidocaine 5% Medicated Plaster Compared with Pregabalin for the Treatment of Postherpetic Neuralgia in the UK, A Markov Model Analysis. Clinical Drug Investigation. 2010; 30 (2): 71-87.15. Dakin H, Nuijten M, Liedgens H, Nautrup BP. Cost Effectiveness of a Lidocaine 5% Medicated Plaster Relative to Gabapentin for Postherpetic Neuralgia in the United Kingdom. Clinical Therapeutics. 2007;29 (7): 1-17.16. Dray A. Neuropathic pain: emerging treatments. British Journal of Anaesthesia.2008;101 (1): 48–58.17. Rabow MW, Pantilat SZ. Palliative Care & Pain Management. En: McPhee SJ, Papadakis MA eds. Current Medical diagnosis and Treatment.49th Ed. New York: Mc Graw Hill; 2010. P76-93.18. Chrischilles EA. Cost-Effectiveness Analysis. En: Bootman JL, Townsend RJ, McGhan WE. Principles of Pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney; 1996. P77-101.19. Rascati KL. Cost-Effectiveness Analysis. En: Rascati KL. Essentials of Pharmacoeconomics. Philadelphia: Lippincott Williams& Wilkins; 2009. P47-66.20. Nayak S.Lidocaine 5% patch for localized chronic neuropathic pain in adolescents. Pediatric Anesthesia.2008;18(6):554-558.21. Laird MA, Gidal BE. Use of gabapentin in the treatment of neuropathic pain. The Annals of Pharmacotherapy.2000;34(6): 802-807.22. Hardman JG, Limbird LE, Goodman A eds.The Pharmacological Basis of Therapeutics. 10th ed. New York:McGraw-Hill;2001.23. Durmus M, Kadir but A, Saricicek V, Ilksen Toprak H, Ozcan Ersoy M. The post-operative analgesic effects of a combination of gabapentin and paracetamol in patients undergoing abdominal hysterectomy: a randomized clinical trial. Acta Anaesthesiologica Scandinavica. 2007; 51: 299–304.24. Gómez-Pérez FJ, Pérez-Monteverde A, Nascimento O, Aschner P, Tagle M, Fichtner K, etal. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. The British Journal of Diabetes & Vascular Disease. 2004; 4(3): 173 - 178.25. Inserto aprobado por INVIMA Colombia Gabapentin 2012.26. Blommel ML, Blommel AL. Pregabalin: An antiepileptic agent useful for neuropathic pain. American Journal of Health-System Pharmacy.2007; 64(14): 1475-1482.27. Inserto aprobado por INVIMA Colombia Pregabalin 2012.28. Comer AM, Lamb HM. Lidocaine Patch 5%.Drugs.2000; 59(2):245-249.29. Davies PS, Galer BS. Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia. Drugs. 2004; 64 (9): 937-947.30. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, Tolerability, and Impact on Quality of Life of the 5% Lidocaine Patch in Diabetic Polyneuropathy. Archives of Neurology. 2004;61:914-918.31. Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5% for carpal tunnel syndrome: How it compares with injections: A pilot study. The Journal of Family Practice.2006; 55(3):209-214.32. Habib AS, Polascik TJ, Weizer AZ, White WD, Moul JW, ElGasim MA, etal. Lidocaine Patch for Postoperative Analgesia After Radical Retropubic Prostatectomy. Anesthesia & Analgesia. 2009;108(6):1950 –1953.33. Correa-Illanes G, Calderon W, Roa R, Piñeros JL, Dote J, Medina D. Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster. Local and Regional Anesthesia. 2010;3: 77–83.34. Annemans L, Caekelbergh K, Morlion B, Hans G,De Cock P, Marbaix S. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clinica Belgica. 2008; 63(3): 170-178.35. Doth AH, Hansson PT, Jensen MP, Taylor RS.The burden of neuropathic pain: A systematic review and meta-analysis of health utilities.Pain.2010;149:338–344.36. Cepeda MS, Farrar JT. Economic Evaluation of Oral Treatments for Neuropathic Pain. The Journal of Pain.2006; 7(2):119-128.37. Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, etal. Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. Journal of Medical Economics.2010; 13(3):472–481.38. Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, etal. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or Pregabalin. Journal of Medical Economics. 2010; 13(3):482–491.39. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clinical Therapeutics. 2006;28(11):1922-1934.40. Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, etal. Cost-Effectiveness Analysis of a Lidocaine 5% Medicated Plaster Compared with Gabapentin and Pregabalin for Treating Postherpetic Neuralgia. Clinical Drug Investigation. 2008; 28 (9): 583-601.41. Pérez C, Navarro A, Saldaña MT, Masramón X, Rejas J. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study. Clinical Therapeutics. 2010; 32(7):1357-70.42. Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Current Medical Research and Opinion. 2007;23(10):2585-2596.43. O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. Journal of the American Geriatrics Society. 2007; 55(8):1176-1184.44. Sicras-Mainar A, Rejas-Gutierrez J, Navarro-Artieda R, Planas-Comes A. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain. Journal of Evaluation in Clinical Practice.2011. doi: 10.1111/j.1365-2753.2011.01752.x45. Pérez C, Saldaña MT, Navarro A, Martínez S, Rejas J. Trigeminal Neuralgia Treated With Pregabalin in Family Medicine Settings: Its Effect on Pain Alleviation and Cost Reduction. Journal of Clinical Pharmacology. 2009; 49:582- 590.46. Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.BMC Neurology.2011; 11(7): 1-11.47. Saldaña MT, Navarro A, Pérez C, Masramón X, Rejas J. A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings. Pain Practice. 2010; 10(1): 31-41.48. O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26(12):1045-1064.49. Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Current Medical Research & Opinion. 2011;27(5):939-950.50. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs. The Journal of Pain. 2010; 11(4):360-368.51.Bouhassira D, LanteÅLri-Minet M, Attal N etal. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain.2008;136:380–387.52.Smith A, Stijacic Cenzer I, Knight SJ etal. The Epidemiology of Pain During the Last 2 Years of Life. Ann Intern Med. 2010;153:563-56953. Hernández N., Hernández J., Moreno C. Uso de los parches de lidocaína en el alivio del dolor neuropático localizado. Rev. Iberoamericana del Dolor N° 1, Vol 4, 200954. Smith KJ, Roberts MS. Secuencial medication strategies for postherpetic neuralgia: a cost effective analysis. J Pain 2007, 8 (5): 396-404.55. Baron R, Mayoral V et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Current Medical Research and Opinion. July 2009 (25) 7: 1677-1687instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURGabapentinaPregabalinaLidocainaCosto-efectividaddolorGabapentinPregabalinLidocaineCost-effectivenesspainAtención médica::Aspectos EconómicosEnfermedades del sistema nervioso::TratamientoGabapentina::UtilizaciónLidocaína::UtilizaciónPregabalina::UtilizaciónEstudio Costo-Efectividad de Lidocaína tópica como adyuvante a Pregabalina y Gabapentina en dolor neuropático periférico en una I.P.S de Bogotá 2011.bachelorThesisTrabajo de gradohttp://purl.org/coar/resource_type/c_7a1fORIGINALHinestrosa-Francisco-2013.pdfHinestrosa-Francisco-2013.pdfDocumento Tesisapplication/pdf1160036https://repository.urosario.edu.co/bitstreams/3fd294a7-5aab-433a-9396-a8d07e4c5b81/download9f04b5a0b41c39c28cf5bd77d4af891cMD54Hinestrosa-Francisco-2013.pdfHinestrosa-Francisco-2013.pdfPresentación Proyecto de Tesisapplication/pdf2524282https://repository.urosario.edu.co/bitstreams/79ae3bce-0a0b-44fc-b5b9-c4c808a2f5a5/download4a1b9425ec860bc252becc65b1e76949MD55LICENSElicense.txtlicense.txttext/plain1664https://repository.urosario.edu.co/bitstreams/300be21c-83df-4ff5-8466-abac692f436a/download501eaa40a78b60e46098e6f8aa2bb95bMD56CC-LICENSElicense_urllicense_urltext/plain49https://repository.urosario.edu.co/bitstreams/27ef5eb4-04f5-4fe8-8cde-587b72906b0d/download51e1d201d51cb527a2cdf276cec345f7MD57license_textlicense_textapplication/octet-stream20254https://repository.urosario.edu.co/bitstreams/f46bc37c-b06e-44c7-aa5f-0a528b6a2376/download4b541ee1308bed0a9219513c5afdc9b6MD58license_rdflicense_rdfapplication/octet-stream21427https://repository.urosario.edu.co/bitstreams/6528b5e7-d1e2-46f9-9ee6-daf0ee24aac0/downloadbea4d6b2af765285c72632958378a5e6MD59TEXTHinestrosa-Francisco-2013.pdf.txtHinestrosa-Francisco-2013.pdf.txtExtracted texttext/plain164353https://repository.urosario.edu.co/bitstreams/527c7aec-22f9-4d1b-98cd-4664bfda2de7/downloadd0ed4548228c2a99deb7c94749c7d107MD518Hinestrosa-Francisco-2013.pdf.txtHinestrosa-Francisco-2013.pdf.txtExtracted texttext/plain36323https://repository.urosario.edu.co/bitstreams/6886d2d8-baaf-4c45-a834-ab85d0e9a34b/downloadf2afda8d294778aca31cf4c61c1f5516MD520THUMBNAILHinestrosa-Francisco-2013.pdf.jpgHinestrosa-Francisco-2013.pdf.jpgGenerated Thumbnailimage/jpeg2228https://repository.urosario.edu.co/bitstreams/e71a6406-364e-481f-9742-353546904ded/download5316d6a43dbf4d1fb49bb15b161d248eMD519Hinestrosa-Francisco-2013.pdf.jpgHinestrosa-Francisco-2013.pdf.jpgGenerated Thumbnailimage/jpeg2421https://repository.urosario.edu.co/bitstreams/e2066c7c-5680-43fd-ad82-f78c6461e539/download93919197fc06e0461440c0e2e7f056d7MD52110336/4440oai:repository.urosario.edu.co:10336/44402021-06-03 00:47:21.663http://creativecommons.org/licenses/by-nc-nd/2.5/co/https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.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

Publicaciones similares